Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.

Pathology - 1 Jun 2024

Sreedharanunni Sreejesh, Singla Shelly, Balakrishnan Anand, Singh Archana, Jamwal Manu, Singh Namrata, Singh Charanpreet, Jandial Aditya, Lad Deepesh, Sharma Praveen, Sachdeva Man Updesh Singh, Malhotra Pankaj, Das Reena

Abstract excerpt

We investigated the frequency and outcome of mono-hit and multi-hit TP53 aberrations [biallelic or ≥1 TP53 mutations (TP53mut) or TP53mut with variant allele frequency (VAF) ≥55%] in an Indian cohort of newly diagnosed multiple myeloma (NDMM) patients. We employed fluorescence insitu hybridisation (FISH; n=457) and targeted next-generation sequencing (NGS; n=244) on plasma cell-enriched samples. We also studied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to In Situ Hybridization, Fluorescence

Share to Multiple Myeloma

Share to Mutation

Share to Prognosis

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 38413253
DOI: 10.1016/j.pathol.2023.12.415

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.PMID 38413253Read ↗

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.Semantic proximity Read ↗

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.Semantic proximity Read ↗

Novel genomic findings in multiple myeloma identified through routine diagnostic sequencingSemantic proximity Read ↗

Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.Semantic proximity Read ↗

Subclonal TP53 copy number is associated with prognosis in multiple myelomaSemantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.Semantic proximity Read ↗

Clonal hematopoiesis impacts frailty in newly diagnosed multiple myeloma patients: a retrospective multicenter analysis.Semantic proximity Read ↗

Therapy-related myeloid neoplasms with single-hit TP53 mutations share the clinical, molecular, and survival characteristics of their multi-hit counterparts.Semantic proximity Read ↗

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.Semantic proximity Read ↗

Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.Semantic proximity Read ↗

Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.